| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442679 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
The addition of aflibercept to FOLFIRI showed a continued and persistent improvement in overall survival over time in patients with mCRC. Although grade 3-4 AEs were more frequent in the aflibercept arm, they occurred in early treatment cycles and decreased sharply following initial presentation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paul Ruff, David R. Ferry, Radek Lakomỳ, Jana Prausová, Guy A. Van Hazel, Paulo M. Hoff, David Cunningham, Dirk Arnold, Hans J. Schmoll, Vladimir M. Moiseyenko, Joseph J. McKendrick, Albert J. ten Tije, Raghu L. Vishwanath, Pankaj Bhargava,